FIELD: pharmaceutics.
SUBSTANCE: present invention relates to an intranasal pharmaceutical dosage form comprising a unit dosage containing naloxone or a pharmaceutically acceptable salt thereof in an amount of from 0.65 mg naloxone HCl 0.8 mg naloxone HCl or 1.3 mg of naloxone HCl 1.6 mg naloxone HCl, dissolved in a liquid for application in volume ≤ 250 mcl. Present invention also relates to said pharmaceutical intranasal dosage form for use in treatment of opioid overdosage and/or at least one of its symptoms.
EFFECT: intranasal pharmaceutical dosage form of invention provides high bioavailability of naloxone, a rapid onset of action, long duration of action and slow type of removal.
21 cl, 16 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2657441C1 |
| COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE | 2017 |
|
RU2769397C2 |
| COMPOSITIONS AND METHOD FOR RELIEVING RESPIRATORY DISTRESS CAUSED BY OPIOID OVERDOSE | 2011 |
|
RU2541159C2 |
| COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | 2017 |
|
RU2767062C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF NALOXONE HYDROCHLORIDE-BASED NASAL SPRAY AND METHOD OF OBTAINING THEREOF | 2013 |
|
RU2572217C2 |
| NEW AND EFFECTIVE MEDICINAL FORMS OF TAPENTADOL | 2009 |
|
RU2673882C1 |
| NEW AND EFFECTIVE DOSAGE FORMS OF TAPENTADOL | 2009 |
|
RU2599846C2 |
| INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | 2012 |
|
RU2692245C2 |
| COMBINATIONS OF AGONIST/ANTAGONIST FOR OPIOID | 1998 |
|
RU2241458C2 |
| PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2445077C2 |
